CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
1 Year : From Apr 2019 to Apr 2020
By Michael Dabaie
CytomX Therapeutics Inc. (CTMX) shares were up 9% to $12.03 in heavier-than-average volume Tuesday.
The clinical-stage oncology-focused biopharmaceutical company said its partner AbbVie (ABBV) selected a second target under the companies' 2016 agreement to discover and develop Probody drug conjugates.
The target selection triggers a $10 million payment to CytomX from AbbVie. The companies are also advancing clinical-stage asset CX-2029 under a global co-development and licensing agreement, CytomX said.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
July 09, 2019 11:40 ET (15:40 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.